Taysha Gene Therapies, Inc. (TSHA) Earnings
Taysha Gene Therapies, Inc.'s most recently reported earnings, recent earnings filings (8-K) and headline annual financials, sourced from SEC EDGAR.
Last reported earnings
Aug 11, 2026
From the latest earnings 8-K
Revenue • FY2025
$9.77M
▲ 17.3%YoY
Diluted EPS • FY2025
-$0.34
▲ 5.6%YoY
Reported earnings dates are based on the latest 8-K (Item 2.02) filings. The next earnings date is an estimate projected from TSHA's historical reporting pattern, not a company-confirmed date.
Headline financials
| Period | Revenue | Net income | Gross profit | Dil. EPS | Free cash flow | Op. margin | Rev. growth |
|---|---|---|---|---|---|---|---|
| FY2025 | $9.77M | -$109M | — | -$0.34 | -$93.83M | -1130.7% | +17.3% |
| FY2024 | $8.33M | -$89.3M | — | -$0.36 | -$81.6M | -1097.5% | -46.1% |
| FY2023 | $15.45M | -$111.57M | — | -$0.96 | -$76.89M | -468.8% | +517.6% |
| FY2022 | $2.5M | -$166.01M | — | -$3.78 | -$109.01M | -6492.7% | — |
Recent earnings filings
| Filed | Form | Accession |
|---|---|---|
| Aug 11, 2026 | 8-K (2.02) | 0001193125-26-344594EDGAR |
| May 6, 2026 | 8-K (2.02) | 0001193125-26-207633EDGAR |
| Mar 19, 2026 | 8-K (2.02) | 0001193125-26-115177EDGAR |
| Nov 4, 2025 | 8-K (2.02) | 0001193125-25-263543EDGAR |
| Aug 12, 2025 | 8-K (2.02) | 0001193125-25-178504EDGAR |
| May 15, 2025 | 8-K (2.02) | 0001193125-25-120329EDGAR |
| Feb 26, 2025 | 8-K (2.02) | 0001193125-25-035882EDGAR |
| Nov 13, 2024 | 8-K (2.02) | 0001193125-24-257205EDGAR |
Never miss a TSHA filing.
Get an email when TSHA files its next 8-K, Form 4, 10-K or 10-Q with the SEC. Free, no account needed.
Free foreverNo account requiredOne-click unsubscribe
Data as of Nov 8, 2026Source: SEC EDGAR.